A consumer health feature published on Yahoo Health reports that peptide therapy marketed for menopause symptoms is not backed by clinical evidence, and quotes two physicians saying so plainly. "There hasn't been any good data that peptides are helpful," says Robin Noble, MD, a gynecologist in Portland, Maine, and chief medical adviser for the nonprofit Let's Talk Menopause.

Peptides are short chains of amino acids, the building blocks of proteins. Stacey Silverman Fine, MD, a board-certified ob-gyn at Maven Clinic, describes them as beads on a string: a few beads is a peptide, a long string is a protein. The body makes thousands of them, acting as chemical messengers that signal hormone production, blood sugar control, cell growth and immune function.

Why the pitch sounds plausible

Insulin was the first peptide drug, and the FDA has since approved a few dozen injectable peptide medicines for specific uses: GLP-1 drugs for obesity and type 2 diabetes, teriparatide and abaloparatide for osteoporosis, oxytocin to induce labor. Because peptides are involved in hormone production, Silverman Fine says it makes sense that they might help manage menopause.

That is the logical leap the marketing is riding. She draws a clear line between peptides, which signal the body to produce and release hormones, and hormone replacement therapy, which directly replaces the estrogen the body no longer makes. Only one of those is FDA-approved for menopause.

The compounds being promoted

BPC-157 is discussed for joint stiffness, but most evidence so far comes from animal or lab trials rather than human studies. GHK-Cu, a copper peptide, has research the article says shows promise for collagen production and skin elasticity, again mostly in animals or the lab. CJC-1295 with ipamorelin and TB-500 are not FDA-approved and are available only in clinical trials. Sermorelin is approved only for children with growth hormone deficiency.

The gray market problem

Silverman Fine draws the sharpest distinction in the piece: many peptides are safe, well-studied, provider-prescribed medications, while those marketed for anti-aging, recovery and athletic performance are largely unproven, unregulated, and have not had their safety established. Unregulated injectables sold online are often labeled "research chemicals" or "not for human consumption" to get around safety rules, she says.

Noble calls the market a "Wild West" where buyers are "ripe for being preyed upon." Many products are made in China or India, she says, and without quality control the label may not match the contents.

Bottom line

The one exception the article names is GLP-1 drugs for women who are overweight or have obesity. One study found postmenopausal women on hormone therapy lost 35 percent more weight on tirzepatide than women not taking hormone therapy, and one review of studies suggests GLP-1 drugs may also relieve hot flashes and night sweats. Everything else in the menopause peptide category is, by both doctors' account, still waiting on human trials.